Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.

Lin CC, Kabiling C, Chen CL, Lin YH, Liu YW, Wang CC, Hu TH, Chiu KW.

Transplantation. 2014 Apr 27;97 Suppl 8:S47-53. doi: 10.1097/01.tp.0000446277.36181.e7.

PMID:
24849835
2.

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.

World J Gastroenterol. 2015 May 28;21(20):6236-45. doi: 10.3748/wjg.v21.i20.6236.

3.

Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.

Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, Kageyama F, Kawamura K, Sasada Y, Suda T.

Intern Med. 2015;54(3):273-9. doi: 10.2169/internalmedicine.54.2718.

4.

Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.

Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.

Saudi J Gastroenterol. 2013 Sep-Oct;19(5):223-9. doi: 10.4103/1319-3767.118133.

5.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
6.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

7.
9.

Feasibility of individualized treatment for hepatitis C patients in the real world.

Chen TM, Huang PT, Lin CH, Tsai MH, Lin LF, Liu CC, Ho KS, Tung JN.

J Gastroenterol Hepatol. 2010 Jan;25(1):61-9. doi: 10.1111/j.1440-1746.2009.05946.x. Epub 2009 Sep 25.

PMID:
19780879
10.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators..

N Engl J Med. 2007 Jul 12;357(2):124-34.

11.

High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).

Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM.

Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039. Epub 2011 Mar 24.

PMID:
21439960
12.

Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.

Tamè M, Buonfiglioli F, Del Gaudio M, Lisotti A, Cecinato P, Colecchia A, Azzaroli F, D'Errico A, Arena R, Calvanese C, Quarneti C, Ballardini G, Pinna AD, Mazzella G.

World J Gastroenterol. 2013 Aug 28;19(32):5278-85. doi: 10.3748/wjg.v19.i32.5278.

13.

The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.

Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.

Transplant Proc. 2011 Dec;43(10):3824-8. doi: 10.1016/j.transproceed.2011.08.103.

PMID:
22172854
14.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.

Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP.

Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3.

15.

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K.

Intervirology. 2012;55(4):306-10. doi: 10.1159/000328661. Epub 2011 Aug 25.

PMID:
21865660
16.

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT.

Clin Transplant. 2004 Apr;18(2):166-73.

PMID:
15016131
17.

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N.

Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006. Epub 2014 Apr 12.

PMID:
24727022
18.

Early and extended therapy for recurrent hepatitis C after liver transplantation.

García-Pajares F, Almohalla C, Lorenzo Pelayo S, Ruiz Zorrilla R, Pinto P, Ramos C, Sanchez Antolin G, Paton AC.

Transplant Proc. 2012 Jul-Aug;44(6):1571-3. doi: 10.1016/j.transproceed.2012.05.027.

PMID:
22841217
19.

Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.

Dinges S, Morard I, Heim M, Dufour JF, Müllhaupt B, Giostra E, Clavien PA, Mentha G, Negro F; Swiss Association for the Study of the Liver (SASL 17)..

Transpl Infect Dis. 2009 Feb;11(1):33-9. doi: 10.1111/j.1399-3062.2008.00359.x. Epub 2008 Dec 3.

PMID:
19144096
20.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

PMID:
18834319

Supplemental Content

Support Center